MX2014013271A - Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos. - Google Patents
Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos.Info
- Publication number
- MX2014013271A MX2014013271A MX2014013271A MX2014013271A MX2014013271A MX 2014013271 A MX2014013271 A MX 2014013271A MX 2014013271 A MX2014013271 A MX 2014013271A MX 2014013271 A MX2014013271 A MX 2014013271A MX 2014013271 A MX2014013271 A MX 2014013271A
- Authority
- MX
- Mexico
- Prior art keywords
- optical density
- cancer cells
- drug
- well plate
- relative effectiveness
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/59—Transmissivity
- G01N21/5907—Densitometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Se provee un sistema de computadora para determinar la efectividad relativa de fármacos anti-cancerígenos. La interfase tiene opciones seleccionables, incluyendo una opción para manejar los parámetros de prueba del fármaco, y permite al usuario la selección de parámetros de prueba de fármaco deseados con relación a una placa con pocillos virtual asociada con una placa de pocillos física de un espectrofotómetro. El sistema de computadora causa que el espectrofotómetro inicie una prueba de fármaco, en donde la placa de pocillos física incluye al menos un pocillo de prueba que contiene células cancerígenas viables; y al menos un fármaco candidato en una concentración predeterminada; y al menos un pocillo de control con las células cancerígenas viables sola. El sistema registra la densidad óptica del pocillo a una longitud de onda predeterminada a intervalos de tiempo seleccionados por una duración de tiempo seleccionada, y almacena las mediciones de la densidad óptica y tiempo en la base de datos. Se calcula un valor de actividad de las mediciones de la densidad óptica y tiempo, y se despliega una correlación entre el valor de la actividad y la habilidad del fármaco candidato para inducir apoptosis en las células cancerígenas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641610P | 2012-05-02 | 2012-05-02 | |
| US13/803,623 US9476871B2 (en) | 2012-05-02 | 2013-03-14 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| PCT/US2013/039189 WO2013166233A1 (en) | 2012-05-02 | 2013-05-02 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013271A true MX2014013271A (es) | 2015-04-08 |
| MX345540B MX345540B (es) | 2017-02-03 |
Family
ID=49514877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013271A MX345540B (es) | 2012-05-02 | 2013-05-02 | Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9476871B2 (es) |
| EP (2) | EP2847701A4 (es) |
| JP (1) | JP6365988B2 (es) |
| KR (1) | KR102028711B1 (es) |
| CN (1) | CN104412270B (es) |
| AU (2) | AU2013256248B2 (es) |
| BR (1) | BR112014027287A2 (es) |
| CA (1) | CA2872109C (es) |
| CL (1) | CL2014002981A1 (es) |
| CO (1) | CO7190233A2 (es) |
| CR (1) | CR20140551A (es) |
| CU (1) | CU20140125A7 (es) |
| HK (1) | HK1203670A1 (es) |
| IL (1) | IL235455B (es) |
| MX (1) | MX345540B (es) |
| NI (1) | NI201400128A (es) |
| NZ (1) | NZ702526A (es) |
| PE (1) | PE20150299A1 (es) |
| PH (1) | PH12014502687A1 (es) |
| RU (1) | RU2014148543A (es) |
| SG (1) | SG11201407141VA (es) |
| TW (1) | TWI605413B (es) |
| WO (1) | WO2013166233A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9476871B2 (en) | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| IN2014DN09582A (es) * | 2012-05-15 | 2015-07-17 | Diatech Oncology Llc | |
| US9460407B2 (en) * | 2013-05-03 | 2016-10-04 | Sap Se | Generating graphical representations of data |
| WO2015171848A2 (en) * | 2014-05-08 | 2015-11-12 | Diatech Oncology, Llc | Synergism and antagonism between multiple anti-cancer agents determined by mick assay |
| JP6521528B2 (ja) * | 2016-04-18 | 2019-05-29 | 富士フイルム株式会社 | 代替医薬品検索装置及び代替医薬品検索方法 |
| US11151604B2 (en) * | 2016-06-10 | 2021-10-19 | International Business Machines Corporation | Revenue management using dynamic customer selection |
| CN110047562B (zh) * | 2019-05-14 | 2021-04-27 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
| US20200388355A1 (en) * | 2019-06-07 | 2020-12-10 | Cary A. Presant | Method and devices for direct apoptosis assay of purified cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5068181A (en) | 1989-12-01 | 1991-11-26 | Akzo N.V. | Method of monitoring reagent delivery in a scanning spectrophotometer |
| US5356793A (en) | 1990-03-15 | 1994-10-18 | Nitta Gelatin Inc. | Method for testing the sensitivity of anticancer drug |
| US6077684A (en) | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
| CN1220395A (zh) * | 1997-12-15 | 1999-06-23 | 中国科学院生物物理研究所 | 一种基于微量元素分布特征的抗癌药物筛选方法 |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| AU2002239491A1 (en) * | 2000-11-09 | 2002-05-27 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
| WO2002046750A2 (en) | 2000-11-13 | 2002-06-13 | Vanderbilt University | Methods of predicting chemotherapy response |
| CA2467657A1 (en) | 2000-11-17 | 2002-08-01 | Alfred E. Slanetz | Process for determining target function and identifying drug leads |
| JP2005519610A (ja) * | 2002-03-13 | 2005-07-07 | エフ．ホフマン−ラ ロシュ アーゲー | 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法 |
| US6900058B2 (en) | 2003-03-11 | 2005-05-31 | Bionostics, Inc. | Control solution for photometric analysis |
| JP2008536128A (ja) * | 2005-04-09 | 2008-09-04 | セル バイオサイエンシズ，インコーポレイテッド | 自動化微小体積アッセイシステム |
| CN1954887A (zh) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | 一种体外抗癌药物筛选模型的制备方法 |
| US7736905B2 (en) | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| KR100721927B1 (ko) | 2006-10-31 | 2007-05-28 | 이수앱지스 주식회사 | 암조직에서 암세포를 분리하는 방법 |
| GB2474613A (en) | 2008-07-10 | 2011-04-20 | Nodality Inc | Methods and apparatus related to management of experiments |
| WO2010148252A1 (en) * | 2009-06-17 | 2010-12-23 | Jody Vykoukal | Method and apparatus for quantitative microimaging |
| KR101533469B1 (ko) | 2010-02-03 | 2015-07-02 | 연세대학교 산학협력단 | Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법 |
| US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
| US8475739B2 (en) * | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US9476871B2 (en) | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| IN2014DN09582A (es) | 2012-05-15 | 2015-07-17 | Diatech Oncology Llc |
-
2013
- 2013-03-14 US US13/803,623 patent/US9476871B2/en active Active
- 2013-04-30 TW TW102115445A patent/TWI605413B/zh active
- 2013-05-02 EP EP13784507.9A patent/EP2847701A4/en not_active Ceased
- 2013-05-02 BR BR112014027287A patent/BR112014027287A2/pt not_active Application Discontinuation
- 2013-05-02 JP JP2015510444A patent/JP6365988B2/ja active Active
- 2013-05-02 KR KR1020147033937A patent/KR102028711B1/ko active IP Right Grant
- 2013-05-02 CN CN201380035279.0A patent/CN104412270B/zh not_active Expired - Fee Related
- 2013-05-02 CA CA2872109A patent/CA2872109C/en active Active
- 2013-05-02 RU RU2014148543A patent/RU2014148543A/ru not_active Application Discontinuation
- 2013-05-02 NZ NZ702526A patent/NZ702526A/en not_active IP Right Cessation
- 2013-05-02 MX MX2014013271A patent/MX345540B/es active IP Right Grant
- 2013-05-02 WO PCT/US2013/039189 patent/WO2013166233A1/en active Application Filing
- 2013-05-02 AU AU2013256248A patent/AU2013256248B2/en not_active Ceased
- 2013-05-02 EP EP22180904.9A patent/EP4134962A1/en not_active Withdrawn
- 2013-05-02 PE PE2014001938A patent/PE20150299A1/es not_active Application Discontinuation
- 2013-05-02 SG SG11201407141VA patent/SG11201407141VA/en unknown
-
2014
- 2014-10-31 NI NI201400128A patent/NI201400128A/es unknown
- 2014-11-02 IL IL235455A patent/IL235455B/en not_active IP Right Cessation
- 2014-11-03 CL CL2014002981A patent/CL2014002981A1/es unknown
- 2014-11-03 CU CU2014000125A patent/CU20140125A7/es unknown
- 2014-12-02 CO CO14265404A patent/CO7190233A2/es unknown
- 2014-12-02 PH PH12014502687A patent/PH12014502687A1/en unknown
- 2014-12-02 CR CR20140551A patent/CR20140551A/es unknown
-
2015
- 2015-05-04 HK HK15104231.4A patent/HK1203670A1/xx unknown
-
2016
- 2016-10-04 US US15/285,292 patent/US10488402B2/en active Active
-
2018
- 2018-12-21 AU AU2018282460A patent/AU2018282460B2/en active Active
-
2019
- 2019-10-02 US US16/591,389 patent/US20200249222A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502687A1 (en) | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates | |
| Quirk et al. | Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. | |
| SG10201907682RA (en) | System and method for providing patient-specific dosing as a function of mathematical models | |
| AU2019268205A1 (en) | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance | |
| GB2547355A (en) | System and method for collection, storage and management of medical data | |
| MX2015006757A (es) | Método para la evaluación de la presencia de o riesgo de tumores de colon. | |
| IN2014DN10099A (es) | ||
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| WO2013040025A3 (en) | Methods and apparatus to monitor products in stores | |
| Yang et al. | Repopulation of tumor cells during fractionated radiotherapy and detection methods | |
| IN2015DN02508A (es) | ||
| van der Veen et al. | Anchoring molecular mechanisms to the adverse outcome pathway for skin sensitization: Analysis of existing data | |
| IN2014MN02150A (es) | ||
| Norfolk et al. | Developing therapeutic rapport: a training validation study. | |
| Wiliński et al. | Medication adherence in hypertensive patients of different cardiovascular risk treated in primary health care. | |
| MX2014004471A (es) | Fenotipificacion de precision utilizando analisis de proximidad de espacio de puntuacion. | |
| WO2013188437A3 (en) | Ex vivo methods to identify circulating drug metabolites with drug interaction potential | |
| Castanov et al. | Scientific Overview on CSCI-CITAC Annual General Meeting and 2018 Young Investigators’ Forum | |
| WO2014040090A3 (en) | System of assessing physiologic status from sweat analysis and determining an appropriate response | |
| Nakazawa | Aiming for zero blindness | |
| TH152624A (th) | ระบบ และวิธีการสำหรับการกำหนดหาแบบอัตโนมัติของประสิทธิผลสัมพัทธ์ ของสารที่มีศักยภาพในการเป็นยาต้านมะเร็ง | |
| Kettenhofen et al. | Human iPSC-derived Cardiomyocytes: a Predictive, HTS-Scalable Tool for Comprehensive Cardiac Safety | |
| Hamilton et al. | Melt Inclusions and Their Application-New Perspective on the Subsurface Architecture of Cerro Negro Volcano, Nicaragua | |
| Bencsik et al. | ACOUSTIC CR®-NEUROMODULATION--FIRST EXPERIENCIES IN HUNGARY WITH A NOVEL METHOD IN THE THERAPY OF CHRONIC SUBJECTIVE TINNITUS | |
| Risson et al. | PRM65-DIFFERENT COST EFFECTIVENESS MODELS USED FOR ECONOMIC EVALUATION IN MODERATE TO SEVERE PAINFUL DIABETIC NEUROPATHY OR POST-HERPETIC NEURALGIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |